Navigation Links
Genmab A/S - Notice to Convene Annual General Meeting
Date:4/7/2008

world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Genmabs 2007 Annual Report
2. Genmab Announces Year End 2007 Financial Results
3. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
4. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
5. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
6. Medarex Announces Completion of Sale of Shares in Genmab A/S
7. Genmabs Financial Calendar for 2008
8. Genmab Reaches Milestones in Ofatumumab Collaboration
9. Genmab Announces HuMax-CD32b Pre-Clinical Program
10. Roche Files IND for Second Genmab Antibody
11. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 04, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... to Optimize the Management of Pain”. , The ... Medscape.com for the next year. The focus of ... to recognize inadequate pain treatments, integrate appropriate pain ...
(Date:3/4/2015)... March 4, 2015  BioClinica®, Inc., a ... provider, today announced that clinical trial professionals ... at its annual European User Conference in ... discuss the use of its eClinical technologies ... technologies include: the Microsoft Office-Smart OnPoint CTMS; ...
(Date:3/4/2015)... Follow us on LinkedIn - ... growing technologies in the life sciences industry. Growing global ... growth in nucleic acid detection technologies like qPCR and ... will continue to benefit the qPCR and dPCR instruments ... pharma, biotech, food & beverage to animal feed, will ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... Company Focused on iPS Technology, SAN ... and The J.,David Gladstone Institutes, an independent ... research collaboration and licensing,agreement to focus on ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080616/AQM126LOGO ), iPS cells ...
... SAN FRANCISCO, Calif., June 16 Anesiva,Inc. (Nasdaq: ... Kranda as,president, chief executive officer and a member of ... Kranda succeeds John P. McLaughlin,who resigned as chief executive ... business interests, while remaining a consultant to the,company., ...
... Virginia, ROSH HA,AYIN, Israel, June 16 ,EnzySurge Ltd. ... wound management, recently announced the formation of its,Scientific ... practitioners with diversified expertise in chronic wounds.,The Company ... PhD, Diane L.,Krasner, PhD RN, FAAN, Joseph L. ...
Cached Biology Technology:The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease 2Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors 2Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 2EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 4
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
(Date:2/5/2015)... Feb. 3, 2015 Despite a lack ... industries such as consumer electronics, automotive, storage and ... mount technology (SMT) screen printers. Innovations in electronics ... will push the adoption curve up. Meanwhile, sale ... as glue dispensers are indispensable in the production ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... new report published in the international conservation journal ... Africa promoting the reintroduction of captive lions do little to ... Released ,Early Online, on July 31, ,Walking with lions: ... leo ) in species restoration, was authored by a blue-ribbon ...
... and endangered animal -- be it a tiger in Nepal ... to ask people "how do you FEEL about your predatory ... out what protected species need like habitat and food ... for their human neighbors to tolerate them. A Michigan State ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
Cached Biology News:Report: Captive lion reintroduction programs in Africa operate under 'conservation myth' 2Report: Captive lion reintroduction programs in Africa operate under 'conservation myth' 3To know a tiger is at least to start tolerating them, study shows 2To know a tiger is at least to start tolerating them, study shows 3Backpainrelief.net Tackles Sports Injuries with Infographic 2
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Designed for use with any of the Agencourt kits in tube format....
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,405-4) or contact ... diam. 60 mm volume diam. ...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is a ... nucleus blue in color. The ... contrast to red fluorochromes such ... or R-Phycoerythrin. DAPI can be ...
Biology Products: